A major international research effort is reshaping the long-held belief that lead exposure is primarily a modern problem. The new findings show that early human ancestors encountered lead repeatedly for more than two million years, suggesting that this toxic metal may have played an unexpected role in shaping the evolution of hominid brains, behavior, and possibly language.

The study -- published in Science Advances -- also offers a new angle on why modern humans ultimately surpassed Neanderthals. Lab-grown brain organoids with Neanderthal genetic variants reacted more strongly to lead than organoids with human genetics, hinting that Neanderthals may have been more vulnerable to lead's neurological effects.

Researchers from the Geoarchaeology and Archaeometry Research Group (GARG) at Southern Cross University (Australia), the Department of Environmental Medicine at the Icahn School of Medicine at Mount Sinai Hospital (New York, USA), and the School of Medicine at the University of California San Diego (UCSD, USA) combined fossil chemistry, brain organoid experiments, and evolutionary genetics to uncover how lead factored into hominid history.

Evidence of Ancient Lead Exposure in Fossil Teeth

For many years, lead toxicity was assumed to be closely tied to human industry, including smelting, mining, and the use of leaded petrol and paint. That view shifted when researchers analysed 51 fossil teeth from a range of hominids and great apes, including Australopithecus africanus, Paranthropus robustus, early Homo, Neanderthals, and Homo sapiens. The teeth showed clear chemical traces of intermittent lead exposure that stretch back nearly two million years.

High-precision laser-ablation geochemistry performed at Southern Cross University's GARG Facility (located in Lismore, NSW) and at Mount Sinai's Exposomics laboratories revealed distinct 'lead bands' in the enamel and dentine. These bands formed during childhood and indicate recurring periods of lead intake from environmental sources (such as polluted water, soil, or volcanic activity) or from lead stored in the body's bones and released during times of stress or illness.

"Our data show that lead exposure wasn't just a product of the Industrial Revolution -- it was part of our evolutionary landscape," said Professor Renaud Joannes-Boyau, Head of the GARG research group at Southern Cross University.

"This means that the brains of our ancestors developed under the influence of a potent toxic metal, which may have shaped their social behavior and cognitive abilities over millennia."

How Lead Interacted With Early Brain Development

To understand the functional impact of this exposure, the team studied human brain organoids, which serve as simplified, lab-grown models of early brain development. They tested how lead affected two versions of a key developmental gene known as NOVA1, which regulates gene expression under lead exposure during neurodevelopment. The modern human version of NOVA1 differs from the variant seen in Neanderthals and other extinct hominids, although the reason for this evolutionary change was previously unclear.

Organoids carrying the Neanderthal-like NOVA1 variant showed substantial disruptions in FOXP2-expressing neurons in the cortex and thalamus when exposed to lead. These brain regions are essential for language and speech development. Organoids with the modern human NOVA1 gene showed far less disruption.

"These results suggest that our NOVA1 variant may have offered protection against the harmful neurological effects of lead," said Professor Alysson Muotri, Professor of Pediatrics/Cellular & Molecular Medicine and Director of the UC San Diego Sanford Stem Cell Institute Integrated Space Stem Cell Orbital Research Center.

"It's an extraordinary example of how an environmental pressure, in this case, lead toxicity, could have driven genetic changes that improved survival and our ability to communicate using language, but which now also influence our vulnerability to modern lead exposure."

Genetic Insights Into the Rise of Modern Humans

Genetic and proteomic data from the study showed that lead exposure in organoids with archaic gene variants disrupted multiple pathways tied to neurodevelopment, communication, and social behavior. The FOXP2 disruptions are especially noteworthy because of FOXP2's well-established role in speech and language. These results suggest that long-term pressure from environmental toxins may have nudged cognitive and communicative traits along different evolutionary paths in modern humans and Neanderthals.

"This study shows how our environmental exposures shaped our evolution," said Professor Manish Arora, Professor and Vice Chairman of Environmental Medicine.

"From the perspective of inter-species competition, the observation that toxic exposures can offer an overall survival advantage offers a fresh paradigm for environmental medicine to examine the evolutionary roots of disorders linked to environmental exposures."

What Ancient Lead Exposure Means for Us Today

Although modern lead exposure is mostly linked to industrial activities, it continues to pose a serious health threat, especially for children. The new findings show that human susceptibility to lead may be deeply rooted in our evolutionary past and shaped by interactions between genes and environmental conditions.

"Our work not only rewrites the history of lead exposure," added Professor Joannes-Boyau, "it also reminds us that the interaction between our genes and the environment has been shaping our species for millions of years, and continues to do so."

The research drew on fossil teeth from Africa, Asia, Europe, and Oceania, using detailed geochemical mapping to trace childhood episodes of lead intake. In parallel, brain organoids containing either modern or archaic NOVA1 genes were used to study how lead affected brain development, with particular attention to FOXP2, a gene central to language. Genetic, transcriptomic, and proteomic analyses were combined to build a broad understanding of how lead may have influenced the evolution of hominid cognition and social behavior.

Read more …Scientists find a surprising link between lead and human evolution

Prof. Alon Monsonego of Ben-Gurion University of the Negev found that T helper lymphocytes, which are immune cells involved in regulating the body's defenses, shift in function as people grow older. These shifts can reflect a person's biological age, which may not match their chronological age. Within these changes, the research team (the labs of Prof. Monsonego and Prof. Esti Yeger-Lotem) identified a previously unknown group of T helper cells that become more common with age.

The significance of this discovery became clearer when a Japanese study on supercentenarians, meaning individuals who live well past 100, found that this same T helper cell subset was abundant in their immune systems. Prof. Monsonego now believes these cells may help maintain an immune response that is suitable for a person's stage of life.

The team's findings, led by Dr. Yehezqel Elyahu in collaboration with Prof. Valery Krizhanovsky of the Weizmann Institute of Science, were recently reported in Nature Aging.

Aging, Senescent Cells, and the Immune Response

Scientists describe aging as a process in which cells gradually lose the ability to repair routine damage. When this occurs, the body shows signs of aging. Senescence cells, which naturally appear when regulated properly, become harmful if they accumulate, since they can trigger inflammation and tissue injury.

The researchers discovered that a portion of the T helper cells that increase with age unexpectedly have killing capabilities. These cells help remove senescence cells, thereby limiting their negative effects. Prof. Monsonego's work showed that reducing the number of these T helper cells in mice caused the animals to age more quickly and shortened their lifespan.

This unusual and highly specialized subset of T helper cells continues to rise in number with age and appears to play an important role in slowing the aging process.

Tracking Biological Age and Rethinking Immune Resetting

Because T helper cells shift as people age and appear central to how aging unfolds, Prof. Monosonego and his team suggest monitoring these immune patterns in individuals beginning in their 30s. Such tracking could reveal how quickly someone is aging biologically and help guide early steps to support healthy aging. Differences of decades can develop between biological and chronological ages.

"People say that to reverse aging and "rejuvenate," we need to reset their immune system like the immune systems of people in their 20s. However, our research shows that this might not be the case. People don't need a super-charged immune system; they need one that is working properly and appropriate for their stage in life. So, one of the "axioms" of how to reduce aging may be incorrect," says Prof. Monsonego.

In addition to offering new insight into aging, the newly identified cells may also be useful in diagnostics and future treatments addressing dysregulated aging, longevity, and diseases linked to aging.

Research Team and Support

Prof. Monsonego is part of The Shraga Segal Department of Microbiology, Immunology and Genetics in the Faculty of Health Sciences at BGU, and is also affiliated with TheSchool of Brain Sciences and Cognition.

Contributors to the research included Ilana Feygin, Ekaterina Eremenko, Noa Pinkas, Alon Zemer, Amit Shicht, Omer Berner, Roni Avigdory-Meiri, Anna Nemirovsky, and Keren Reshef from BGU, along with Lior Roitman from Weizmann.

The work received support from the Israel Ministry of Science and Technology (Grant no. 3-16148) and the Litwin and Gural Foundations.

Read more …Neuroscientists find immune cells that may slow aging

An experimental compound has been found to limit cell death, reduce inflammation, and lessen organ damage associated with diabetes.

A research team at NYU Langone Health reported that, in mouse studies, a drug candidate successfully prevented two proteins from interacting: RAGE and DIAPH1. When these proteins come together, they contribute to heart and kidney injury linked to diabetes and slow the healing of wounds.

Blocking a Key Protein Interaction Boosts Healing

The findings, recently featured as a cover story in Cell Chemical Biology, show that keeping DIAPH1 from attaching to RAGE can ease swelling in diabetic tissues and promote more efficient repair. Tests conducted in human cells and mouse models revealed that the compound significantly reduced both immediate and long-term complications in Type 1 and Type 2 diabetes. The compound, known as RAGE406R, is a small molecule named for the protein it targets.

"There are currently no treatments that address the root causes of diabetic complications, and our work shows that RAGE406R can -- not by lowering the high blood sugar, but instead by blocking the intracellular action of RAGE," said co-senior study author Ann Marie Schmidt, MD, the Dr. Iven Young Professor of Endocrinology at the NYU Grossman School of Medicine. "If confirmed by further testing in human trials, the compound could potentially fill gaps in treatment, including that most current drugs work only against Type 2 diabetes."

How RAGE and DIAPH1 Contribute to Damage

RAGE is a receptor, a type of protein that responds to signaling molecules known as advanced glycation end products (AGEs). These molecules form when proteins or fats bind to sugars, a process that occurs more frequently in people with diabetes. AGEs accumulate in the bloodstream in individuals with diabetes and obesity, and also naturally increase with age.

Experiments showed that RAGE406R competes for the binding site on RAGE that DIAPH1 normally occupies. DIAPH1 helps form actin filaments, which are part of the cell's internal structure. The researchers demonstrated that DIAPH1 connects to the inner tail of RAGE, and this pairing increases the formation of actin structures that intensify diabetic complications.

Developing a Safer and More Effective Molecule

Schmidt's team previously screened a library of more than 58,000 molecules and identified several that interfered with the RAGE-DIAPH1 pathway. Their earlier lead compound, RAGE229, did not pass a standard safety test designed to flag structural features that might alter DNA and raise cancer risk. RAGE406R removes the part of the structure that created this concern.

The team then tested RAGE406R in a widely used model for chronic diabetes complications: delayed wound healing in obese mice with Type 2 diabetes. In both male and female mice, applying RAGE406R directly to the skin accelerated wound closure.

Reducing Misplaced Inflammation to Support Repair

Many of the compound's benefits stem from its effects on the immune system. The immune response is designed to detect and eliminate harmful invaders such as bacteria and viruses. When activated, it can cause inflammation, which includes swelling triggered by immune cells gathering at an injured area. In diabetes, inflammation often occurs in the wrong places or lasts too long.

RAGE406R lowered the levels of CCL2, a major proinflammatory signaling molecule. Reducing CCL2 activity calmed inflammation in macrophages, a type of immune cell. This shift helped support structural remodeling in tissues, an essential part of the healing process.

"Our findings point to a promising new pathway for treating diabetes in the future," said co-senior study author Alexander Shekhtman, PhD, a professor in the Department of Chemistry at the State University of New York (SUNY) at Albany. "The current study results serve as a springboard for the development of therapies for both types of diabetes, and for designing markers that can measure how well the new treatment works in live animals."

Contributors and Funding Support

Along with Schmidt, contributors from the Diabetes Research Program in the Department of Medicine at NYU Langone Health include co-first author Michaele Manigrasso, as well as Gautham Yepuri, Kaamashri Mangar, and Ravichandran Ramasamy. Additional NYU Langone collaborators include Sally Vanegas from the Department of Medicine and Yanan Zhao and Huilin Li from the Division of Biostatistics in the Department of Population Health. Shekhtman's group at SUNY at Albany includes first author Gregory Theophall, Parastou Nazarian, Aaron Premo, Sergey Reverdatto, and David Burz. Robert DeVita, PhD, from RJD Medicinal Chemistry and Drug Discovery Consulting LLC, also contributed to the research.

This work was funded by U.S. Public Health Service grants 1R24DK103032, 1R01DK122456-01A1, P01HL146367, and 5R01GM085006. The NYU Histology Core receives partial support from the Perlmutter Cancer Center support grant P30CA016087. Additional backing came from the Diabetes Research Program at the NYU Grossman School of Medicine. Drs. Manigrasso, Ramasamy, and Schmidt are listed on patent applications owned by NYU Langone Health related to this research. Their relationship to this intellectual property is being managed in accordance with NYU Langone Health policies. Dr. DeVita, who consults for NYU Technology Opportunities & Ventures' Therapeutics Alliances and for Intercept Therapeutics, was compensated for his involvement.

Read more …New discovery could help stop diabetes damage at its source

More Articles …